Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135 and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine

Inclusion Criteria:

• Subjects 19 to 55 years of age
• Written informed consent
• Available for all visits and telephone calls scheduled for the study

Exclusion Criteria:

• Previous or suspected disease caused by N. meningitidis
• Household and/or intimate exposure to an individual with culture-proven N. meinigitidis infection within 60 days prior to screening
• Serious acute, chronic or progressive disease as determined by investigator
• History of alcohol or substance abuse